Targeting inflammatory pathways in hepatocellular carcinoma: recent developments
Abstract Chronic inflammation is a well-established driver of malignancy in many various cancer conditions. Hepatocellular carcinoma (HCC) is a significant illustrator of cancer linked to an inflammatory response and known to arises from prolonged liver damage. Inflammation is ranked number five of...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-03035-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849329515457675264 |
|---|---|
| author | Fulufhelo Tabitha Ramaite Sanah Malomile Nkadimeng |
| author_facet | Fulufhelo Tabitha Ramaite Sanah Malomile Nkadimeng |
| author_sort | Fulufhelo Tabitha Ramaite |
| collection | DOAJ |
| description | Abstract Chronic inflammation is a well-established driver of malignancy in many various cancer conditions. Hepatocellular carcinoma (HCC) is a significant illustrator of cancer linked to an inflammatory response and known to arises from prolonged liver damage. Inflammation is ranked number five of the most common factors in the occurrence of cancer conditions globally. Furthermore, it is placed third as the leading reason for cancer-related deaths, accompanied by nearly a million new diagnosis and fatalities annually. Pathological inflammation causes an ongoing liver damage and regeneration, which leads to fibrosis, cirrhosis, and eventually HCC. Although various factors contribute to HCC, a common mechanism is the inflammatory response that is triggered by cell death and the resulting inflammatory cascades. This review assesses recent progress in liver cancer research, focusing on how inflammatory pathways contribute to disease progression. It highlights the role of cytokines along with other inflammatory mediators in the progression of HCC stemming from chronic liver damage. The review also explores new therapeutic approaches targeting inflammatory pathways, including novel compounds and synthetic agents, such as IL-6 receptor antagonist and NF-κB pathway blockers and their potential for effectively treating and preventing liver cancer. Furthermore, it addresses current limitations and challenges in targeting inflammatory signalling and outlines future research directions to advance the clinical development of anti-inflammatory agents for liver cancer prevention and treatment. |
| format | Article |
| id | doaj-art-e032cd8fceda48feadb76b1b8738718d |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-e032cd8fceda48feadb76b1b8738718d2025-08-20T03:47:14ZengSpringerDiscover Oncology2730-60112025-06-0116111610.1007/s12672-025-03035-8Targeting inflammatory pathways in hepatocellular carcinoma: recent developmentsFulufhelo Tabitha Ramaite0Sanah Malomile Nkadimeng1Department of Life and Consumer Sciences, Collage of Agriculture and Environmental Sciences, University of South AfricaDepartment of Life and Consumer Sciences, Collage of Agriculture and Environmental Sciences, University of South AfricaAbstract Chronic inflammation is a well-established driver of malignancy in many various cancer conditions. Hepatocellular carcinoma (HCC) is a significant illustrator of cancer linked to an inflammatory response and known to arises from prolonged liver damage. Inflammation is ranked number five of the most common factors in the occurrence of cancer conditions globally. Furthermore, it is placed third as the leading reason for cancer-related deaths, accompanied by nearly a million new diagnosis and fatalities annually. Pathological inflammation causes an ongoing liver damage and regeneration, which leads to fibrosis, cirrhosis, and eventually HCC. Although various factors contribute to HCC, a common mechanism is the inflammatory response that is triggered by cell death and the resulting inflammatory cascades. This review assesses recent progress in liver cancer research, focusing on how inflammatory pathways contribute to disease progression. It highlights the role of cytokines along with other inflammatory mediators in the progression of HCC stemming from chronic liver damage. The review also explores new therapeutic approaches targeting inflammatory pathways, including novel compounds and synthetic agents, such as IL-6 receptor antagonist and NF-κB pathway blockers and their potential for effectively treating and preventing liver cancer. Furthermore, it addresses current limitations and challenges in targeting inflammatory signalling and outlines future research directions to advance the clinical development of anti-inflammatory agents for liver cancer prevention and treatment.https://doi.org/10.1007/s12672-025-03035-8InflammationLiver cancerTumour microenvironmentCancer therapiesCytokines |
| spellingShingle | Fulufhelo Tabitha Ramaite Sanah Malomile Nkadimeng Targeting inflammatory pathways in hepatocellular carcinoma: recent developments Discover Oncology Inflammation Liver cancer Tumour microenvironment Cancer therapies Cytokines |
| title | Targeting inflammatory pathways in hepatocellular carcinoma: recent developments |
| title_full | Targeting inflammatory pathways in hepatocellular carcinoma: recent developments |
| title_fullStr | Targeting inflammatory pathways in hepatocellular carcinoma: recent developments |
| title_full_unstemmed | Targeting inflammatory pathways in hepatocellular carcinoma: recent developments |
| title_short | Targeting inflammatory pathways in hepatocellular carcinoma: recent developments |
| title_sort | targeting inflammatory pathways in hepatocellular carcinoma recent developments |
| topic | Inflammation Liver cancer Tumour microenvironment Cancer therapies Cytokines |
| url | https://doi.org/10.1007/s12672-025-03035-8 |
| work_keys_str_mv | AT fulufhelotabitharamaite targetinginflammatorypathwaysinhepatocellularcarcinomarecentdevelopments AT sanahmalomilenkadimeng targetinginflammatorypathwaysinhepatocellularcarcinomarecentdevelopments |